PDF(Pubmed)
Abstract：
During the COVID-19 pandemic, a significant increase in cases of mucormycosis was observed in COVID-19 patients, especially in India, but not exclusively. The presented cases highlight the heterogeneous nature of mucormycosis, emphasizing the importance of recognizing predisposing factors, such as immunosuppression, due to comorbidities or medication. Diagnosing mucormycosis poses a challenge due to nonspecific clinical manifestations, requiring a multidisciplinary approach for accurate diagnosis. Treatment involves a multi-pronged approach centered around the early initiation of antifungal therapy alongside surgical intervention and the management of underlying conditions, with an emphasis on controlling immunosuppression. Understanding the relationship between COVID-19 and predisposing factors for mucormycosis is fundamental for developing prevention and treatment strategies.
摘要：
在COVID-19大流行期间，COVID-19患者的毛霉菌病病例显着增加，尤其是在印度,但不是唯一的。所呈现的病例突出了毛霉菌病的异质性，强调认识诱发因素的重要性，如免疫抑制，由于合并症或药物。由于非特异性临床表现，诊断毛霉菌病构成了挑战，需要多学科的方法来准确诊断。治疗涉及多管齐下的方法，围绕早期开始抗真菌治疗以及手术干预和基础疾病的管理，重点是控制免疫抑制。了解COVID-19与毛霉菌病易感因素之间的关系是制定预防和治疗策略的基础。
